ATE224915T1 - Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration - Google Patents

Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration

Info

Publication number
ATE224915T1
ATE224915T1 AT98924307T AT98924307T ATE224915T1 AT E224915 T1 ATE224915 T1 AT E224915T1 AT 98924307 T AT98924307 T AT 98924307T AT 98924307 T AT98924307 T AT 98924307T AT E224915 T1 ATE224915 T1 AT E224915T1
Authority
AT
Austria
Prior art keywords
neuronal regeneration
promote neuronal
inhibitor substance
regeneration
inhibitor
Prior art date
Application number
AT98924307T
Other languages
English (en)
Inventor
H W Prof Dr Mueller
Christine Dr Stichel-Gunkel
Original Assignee
Neuraxo Biotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE224915(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxo Biotec Gmbh filed Critical Neuraxo Biotec Gmbh
Application granted granted Critical
Publication of ATE224915T1 publication Critical patent/ATE224915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98924307T 1997-05-14 1998-05-13 Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration ATE224915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107846A EP0878480A1 (de) 1997-05-14 1997-05-14 Verfahren zur Förderung der Nerven-Regenerierung
PCT/EP1998/002808 WO1998051708A1 (en) 1997-05-14 1998-05-13 A method for the improvement of neuronal regeneration

Publications (1)

Publication Number Publication Date
ATE224915T1 true ATE224915T1 (de) 2002-10-15

Family

ID=8226794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924307T ATE224915T1 (de) 1997-05-14 1998-05-13 Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration

Country Status (8)

Country Link
US (3) US20020115598A1 (de)
EP (2) EP0878480A1 (de)
AT (1) ATE224915T1 (de)
AU (1) AU7654298A (de)
DE (1) DE69808281T3 (de)
DK (1) DK0981549T4 (de)
ES (1) ES2180175T5 (de)
WO (1) WO1998051708A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
CN101664551B (zh) * 2001-12-06 2013-08-14 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
CA3094774A1 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
DE10314082A1 (de) * 2003-03-28 2004-10-21 Mcs Micro Carrier Systems Gmbh Biodegradierbares injizierbares Implantat
KR20080044845A (ko) * 2005-09-02 2008-05-21 노이락소 바이오파르마슈티컬즈 게엠베하 철 킬레이트제를 포함하는 약학적 조성물
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2000134A1 (de) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Verwendung einer Substanz zur Behandlung von Verletzungen des peripheren Nervensystems
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214000A (en) † 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
DE3002989A1 (de) 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
CA1251729A (en) * 1982-05-19 1989-03-28 Steffen Gay In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
DE3432094A1 (de) 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
US5021404A (en) † 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
JPH06103773A (ja) † 1992-09-16 1994-04-15 Hitachi Ltd 半導体記憶装置
EP0634939A1 (de) * 1993-02-11 1995-01-25 Erziehungsdirektion Of The Canton Zurich Eine kombination von neurotrophin und einem antikoerper, gerichtet gegen myelin-assoziertes neurit-wachstum hemmendes protein stimuliert die regenerierung des zentralnervensystems
EP0732940B1 (de) * 1993-10-15 2001-12-19 Thomas Jefferson University Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind
WO1995013291A1 (en) * 1993-11-08 1995-05-18 New York University Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung

Also Published As

Publication number Publication date
EP0981549B9 (de) 2008-02-27
DE69808281D1 (de) 2002-10-31
US20070231330A1 (en) 2007-10-04
DK0981549T4 (da) 2007-10-29
US20020115598A1 (en) 2002-08-22
DE69808281T2 (de) 2003-01-16
ES2180175T3 (es) 2003-02-01
US20050118177A1 (en) 2005-06-02
EP0981549B1 (de) 2002-09-25
US7208153B2 (en) 2007-04-24
WO1998051708A1 (en) 1998-11-19
EP0981549A1 (de) 2000-03-01
AU7654298A (en) 1998-12-08
EP0981549B2 (de) 2007-06-27
DK0981549T3 (da) 2003-02-10
DE69808281T3 (de) 2008-01-24
ES2180175T5 (es) 2008-02-01
EP0878480A1 (de) 1998-11-18

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69629232D1 (de) Verfahren zur Planung der optimalen Abfolge von doppelseitigen oder farbigen Ausdrucken
ATA122888A (de) Verfahren zur beherrschung des aufrollens einer papier- oder ähnlichen bahn
DE60044335D1 (de) 16-phenoxy-lipoxin analoge zur medizinischen verwendung
DE69808281D1 (de) Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration
DE69636451D1 (de) Verfahren zur korrosionsinhibierung unter verwendung von n-halo-azolen
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE69928139D1 (de) Verwendung einer Vorrichtung zur Erhöhung der Feuchtigkeit
DE69712578T2 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69320801T2 (de) Verfahren zur überwachung des wachsamkeitniveaus einer person.
DE69500511D1 (de) Phosphatdiester zur Behandlung von proliferativen Erkrankungen der Epidermis
ATE185473T1 (de) Verwendung einer n-arylpyrazol- oder n- heteroarylpyrazolverbindung zur regulierung von pflanzenwachstum
DE59601439D1 (de) Verfahren zur Regelung einer Feuchtmittelmenge
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
DE69607559T2 (de) Verfahren zur Behandlung von Phenolteer
DE69402849T2 (de) Verfahren zur uberwachung der justierung einer ziel-oder uberwachungssensorreihe
DE69622956T2 (de) Methode zur Regelung der Bestandteile eines Phosphatbades
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE199627T1 (de) Para-hydroxyphenylessigsäure zur reduktion der repellenz von insektiziden
DE69602220T2 (de) Verfahren zur Verbesserung der thermischen Stabilität von Sepiolith
DE69609823D1 (de) Verfahren zur inhibierung der zersetzung von 1,1,1,2,3,3-hexafluorpropan und 1,1,1,3,3-pentafluorpropan und zersetzungsinhibitor
DE69302250D1 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia
DE68906906D1 (de) Beschichtungsmassen zur verhuetung des anhaftens von wasserorganismen.
DE69905731D1 (de) Analgetische verwendung von podophylotoxin zur schmerzbehandlung der weiblichen genitalorgane
DE69628134D1 (de) Auf der inhibierung von phosphatasen beruhendes verfahren zum nachweis und zur quantifizierung von diarrhoetischem schalentiergift

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981549

Country of ref document: EP

EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0981549

Country of ref document: EP

REN Ceased due to non-payment of the annual fee